Investigating the Binding Mode of a Naphthol‐Based Inhibitor Targeting SARS‐CoV‐2 Main Protease
Open Access
- 26 August 2026
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 21 (16) , e70448
Abstract
Regardless of the massive global efforts to combat the virus causing SARS‐CoV‐2 syndrome, the infection remains a substantial health challenge worldwide in the years following 2019. To this direction, targeting the main viral protease M pro has been proposed as a tractable and particularly promising approach toward developing effective and safe COVID‐19 antivirals. By applying an integrated workflow combining a previously developed in silico consensus ranking protocol with two orthogonal in vitro methods, the NCI/DTP repository is screened and the discovery of an original naphthol scaffold with M pro inhibitory properties is reported. The hit is characterized in terms of structure and binding thermodynamics by combining X‐ray crystallography and isothermal titration calorimetry where a binding affinity constant of 1.55 μM is determined. The compound is further evaluated against virus‐infected cells, where an EC 50 value of 7.23 μM and comparable toxicity with nirmatrelvir are measured. Chemical synthesis is additionally employed to facilitate optimal exploration of the structure–activity relationship landscape regarding the new hit. By integrating computational, biophysical, and enzymatic methods, the suggested approach allows the combination of a structural hypothesis with functional evidence and shows its capacity toward identifying and rationally optimizing structurally original noncovalent M pro inhibitors.Keywords
This publication has 54 references indexed in Scilit:
- From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for Mpro of SARS-CoV-2Biochemical Pharmacology, 2026
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19JAMA Network Open, 2024
- Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsAntiviral Research, 2024
- Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trialeClinicalMedicine, 2023
- Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2Antiviral Research, 2021
- The SARS-CoV-2 main protease as drug targetBioorganic & Medicinal Chemistry Letters, 2020
- Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discoveryAntiviral Research, 2019
- Synthesis, structure-activity relationships and preliminary mechanism study of N-benzylideneaniline derivatives as potential TLR2 inhibitorsBioorganic & Medicinal Chemistry, 2018
- Remarkable Ability of the Benzylidene Ligand To Control Initiation of Hoveyda–Grubbs Metathesis CatalystsEuropean Journal of Inorganic Chemistry, 2016
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichmentsJournal of Computer-Aided Molecular Design, 2013